ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Cancer Control Planning Conference Delayed To 1977

August 13, 1976

Kimes, Lenfant, To Retire

July 11, 2003

In Brief: NCI Figure Left unchanged By Carter; Pay Raise Puts further Squeeze On Institute Budget

March 4, 1977

NCI-Approved Clinical Trials

February 24, 2006

New Opportunities Still Abound In Immunology Program, Terry and other NCI Executives Say

February 27, 1976

In Brief: Bishop Named Interim Chairman of NCAB; AACI Elects Wicha president, Herberman VP

December 12, 1997